“Novel” serum biomarkers like ST2 and Pentraxin-3 (Ptx-3) have recently emerged as a potentially useful tool for improving the assessment of cardiovascular disease [7,8,9,10,11]. This evidence concerns the gene PTX3 and cardiovascular disorder.